Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy

CXCL9-expressing tumor-associated macrophages: new players in the fight against cancer

(2021) Paola Marie Marcovecchio et al.   Journal for ImmunoTherapy of Cancer

Prolonged activation of innate immune pathways by a polyvalent STING agonist

(2021) Suxin Li et al.   Nature Biomedical Engineering

Phase I Dose-Escalation Trial of MIW815 (ADU-S100), an Intratumoral STING Agonist, in Patients with Advanced/Metastatic Solid Tumors or Lymphomas

(2021) Funda Meric-Bernstam et al.   CLINICAL CANCER RESEARCH

Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy

(2021) Xiaoqi Sun et al.   Nature Nanotechnology

Intratumoral and subcutaneous injection of HVJ‐E (GEN0101) in metastatic castration‐resistant prostate cancer

(2020) Kazutoshi Fujita et al.   CANCER SCIENCE

CCL2/CCR2 signaling in cancer pathogenesis

(2020) Qiongyu Hao et al.   Cell Communication and Signaling

TGFβ biology in cancer progression and immunotherapy

(2020) Rik Derynck et al.   Nature Reviews Clinical Oncology

Clinical landscape of oncolytic virus research in 2020

(2020) Nicholas Macedo et al.   Journal for ImmunoTherapy of Cancer

Overcoming resistance to STING agonist therapy to incite durable protective antitumor immunity

(2020) Henrique Lemos et al.   Journal for ImmunoTherapy of Cancer

Cancer Vaccines: Steering T Cells Down the Right Path to Eradicate Tumors

(2019) Patrick A. Ott et al.   Cancer Discovery

Immunological basis for enhanced immunity of nanoparticle vaccines

(2019) Hannah G Kelly et al.   Expert Review of Vaccines

A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

(2019) Miguel F. Sanmamed et al.   CELL

Intratumoral Activity of the CXCR3 Chemokine System Is Required for the Efficacy of Anti-PD-1 Therapy

(2019) Melvyn T. Chow et al.   IMMUNITY

Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors

(2019) Denarda Dangaj et al.   CANCER CELL

CXCR3-CXCL9: It’s All in the Tumor

(2019) Etienne Humblin et al.   IMMUNITY

MHC-II neoantigens shape tumour immunity and response to immunotherapy

(2019) Elise Alspach et al.   NATURE

The Cytosolic DNA-Sensing cGAS–STING Pathway in Cancer

(2019) John Kwon et al.   Cancer Discovery

CD8+ cytotoxic T lymphocytes in cancer immunotherapy: A review

(2018) Bagher Farhood et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Actively personalized vaccination trial for newly diagnosed glioblastoma

(2018) Norbert Hilf et al.   NATURE

Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial

(2018) Derin B. Keskin et al.   NATURE

Synthetic nanovaccines for immunotherapy

(2017) Min Luo et al.   JOURNAL OF CONTROLLED RELEASE

Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer

(2017) Ugur Sahin et al.   NATURE

Elements of cancer immunity and the cancer–immune set point

(2017) Daniel S. Chen et al.   NATURE

An immunogenic personal neoantigen vaccine for patients with melanoma

(2017) Patrick A. Ott et al.   NATURE

A STING-activating nanovaccine for cancer immunotherapy

(2017) Min Luo et al.   Nature Nanotechnology

cGAS is essential for the antitumor effect of immune checkpoint blockade

(2017) Hua Wang et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

NK cell-based immunotherapy for cancer

(2017) Fang Fang et al.   SEMINARS IN IMMUNOLOGY

The present status and future prospects of peptide-based cancer vaccines

(2016) Masatoshi Hirayama et al.   INTERNATIONAL IMMUNOLOGY

Beyond antigens and adjuvants: formulating future vaccines

(2016) Tyson J. Moyer et al.   JOURNAL OF CLINICAL INVESTIGATION

Designer vaccine nanodiscs for personalized cancer immunotherapy

(2016) Rui Kuai et al.   NATURE MATERIALS

Nanoparticle-Based Modulation of the Immune System

(2016) Ronnie H. Fang et al.   Annual Review of Chemical and Biomolecular Engineering

Oncogenic CXCL10 signalling drives metastasis development and poor clinical outcome

(2015) S C Wightman et al.   BRITISH JOURNAL OF CANCER

Synthetic Nanoparticles for Vaccines and Immunotherapy

(2015) Darrell J. Irvine et al.   CHEMICAL REVIEWS

In situ vaccination: Cancer immunotherapy both personalized and off-the-shelf

(2015) Linda Hammerich et al.   Molecular Oncology

Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma

(2015) Robert J. Motzer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunomodulatory spherical nucleic acids

(2015) Aleksandar F. Radovic-Moreno et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

(2015) Leticia Corrales et al.   Cell Reports

Intratumoral Immunization: A New Paradigm for Cancer Therapy

(2014) A. Marabelle et al.   CLINICAL CANCER RESEARCH

Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion

(2013) Yared Hailemichael et al.   NATURE MEDICINE

The Ratios of CD8+ T Cells to CD4+CD25+ FOXP3+ and FOXP3- T Cells Correlate with Poor Clinical Outcome in Human Serous Ovarian Cancer

(2013) Claudia C. Preston et al.   PLoS One

Multicolored pH-Tunable and Activatable Fluorescence Nanoplatform Responsive to Physiologic pH Stimuli

(2012) Kejin Zhou et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

gp100 Peptide Vaccine and Interleukin-2 in Patients with Advanced Melanoma

(2011) Douglas J. Schwartzentruber et al.   NEW ENGLAND JOURNAL OF MEDICINE